ArticleOncotarget2017

Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy.

Teng Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.